Vanguard Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Vanguard Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-554,749	Closed	-$9.74M	–	4706
2021 Q3	$9.74M	Buy	554,749 +155,450	+39%	+$1.82M	﹤0.01%	3259
2021 Q2	$3.87M	Buy	399,299 +327,966	+460%	+$3.09M	﹤0.01%	3722
2021 Q1	$766K	Buy	71,333 +3,866	+6%	+$47.8K	﹤0.01%	4060
2020 Q4	$993K	Buy	+67,467	New	+$973K	﹤0.01%	3828

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Vanguard Group's TRIL Position: Q4 2021 in Review

Vanguard Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 554,749 shares — an estimated $9.74M sold.

Vanguard Group first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $9.74M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Vanguard Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Vanguard Group sold 554,749 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $9.74M.
Vanguard Group first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Vanguard Group's Trillium Therapeutics Inc. position peaked at $9.74M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Vanguard Group's 13F filing for Q4 2021, filed 14 Feb 2022.